Summary
The AI content provided does not include an evaluated drug-label-aligned response to a specific user claim about SOLIRIS; instead, it contains meta-assessment text stating no claim was provided. Therefore, no substantiated alignment with prescribing information for indications/dosing/warnings beyond the meta-evaluation can be verified.
Category Scores
Accurate Statements
SOLIRIS increases susceptibility to serious, life-threatening, or fatal meningococcal infections caused by Neisseria meningitidis, including in vaccinated and unvaccinated patients (Section 5.1).
Section 5.1 Serious Meningococcal Infections: states SOLIRIS increases susceptibility to serious, life-threatening, or fatal meningococcal infections in any serogroup, including non-groupable strains, and that life-threatening/fatal infections have occurred in both vaccinated and unvaccinated patients.
Initiation of SOLIRIS is contraindicated in patients with unresolved serious Neisseria meningitidis infection (Section 4).
Section 4 Contraindications: contraindicated for initiation in patients with unresolved serious Neisseria meningitidis infection.
Vaccinate against meningococcal serogroups (A, C, W, Y and B) at least 2 weeks prior to initiation; if urgent therapy is needed and patient is not up to date, provide antibacterial drug prophylaxis and administer vaccines as soon as possible (Sections 5.1 and 2.1).
Section 5.1 and 2.1: vaccination at least 2 weeks prior; urgent therapy not up to date requires prophylaxis and vaccinate as soon as possible.
REMS requirements related to meningococcal infection risk (Section 5.2).
Section 5.2: ULTOMIRIS and SOLIRIS REMS requirements and counseling, vaccination status assessment, prophylaxis prescription for urgent starts, and Patient Safety Card.
Unsupported Statements
Supported: yes; Contradicted: no; Mentioned: yes
No specific user claim text was provided to map to labeling language; this is a meta-evaluation assertion rather than a label-supported medical claim.
A boxed-warning level precaution (vaccination/antibiotic prophylaxis timing, monitoring, and REMS requirements).
The provided label excerpts do not explicitly identify these items as being in a boxed warning; they are described in the Warnings/Precautions and REMS sections shown.
Contradictions
Important Omissions
No actual dosage/administration, contraindication handling details beyond initiation contraindication, or adverse reaction listing beyond meningococcal infections was provided in the AI response; however, the user’s specific request/claim to evaluate was not stated, preventing assessment of completeness for a targeted question.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only substantive label-aligned statements relate to meningococcal infection risk, contraindication for unresolved infection, vaccination timing, and REMS—generally safety-relevant and consistent with the provided excerpts. However, the response did not evaluate a specific user claim and included meta-assertions that are not directly supported by label text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The response is primarily meta-evaluation and does not clearly map to a specific user claim; additionally, it labels certain precautions as 'boxed-warning level' without explicit support in the provided excerpts.
Suggested Improvement
Provide the exact user claim text to be evaluated and quote the specific label sentences that match each claim. Avoid characterizing sections as boxed-warning-level unless the provided label excerpt explicitly indicates that.